Leveraging Chromosomal Instability (CIN) in Glioblastoma for Personalized Medicine and Adaptive Therapeutic Strategies

By synthesizing mechanistic insights with emerging genomic, cytogenetic, and single-cell technologies, often advanced by pioneering research in chemical biology and advanced single-cell methodologies , we outline a disease-focused framework for translating CIN from a descriptive feature of tumor evolution into a clinically actionable biomarker in GBM. Most existing data, which come from cross-sectional studies, show that diploid and aneuploid clones often coexist with stemness-associated markers; however, these studies do not clarify how CIN-driven stemness evolves over time. Translationally validated assays such as single-cell whole-genome sequencing and spectral karyotyping remain costly and lack regulatory standardization, limiting their routine clinical deployment. Additionally, few clinical trials stratify patients by CIN status, leaving gaps in our understanding of which CIN signatures predict response to DDR inhibitors, mitotic stress-inducing agents, centrosome-targeting drugs (e.g., the PLK1 inhibitor ZM-447439 ), or immunotherapies leveraging micronucleus-driven immunogenicity.

To address these challenges, an integrated, multi-modal strategy is essential. Baseline tumor characterization at the time of surgery should include whole-genome sequencing for global CNV profiling and single-cell DNA or RNA sequencing to resolve clonal CNV architectures, stemness-related transcriptional programs, and subclone compositions. Combined single-cell genomic and transcriptomic approaches can precisely link karyotypic states to functional phenotypes, a topic frequently explored in the Journal of Cell Science . Spatially resolved techniques such as multiplexed Fluorescence In Situ Hybridization (FISH) and single-molecule RNA FISH can validate key CNVs and stem markers within tissue context, while conventional cytogenetic or spectral karyotyping remains valuable for identifying chromothriptic and structurally complex events. Complementary biochemical assays—such as micronucleus detection, γH2AX and comet assays for DNA damage, immunofluorescence-based centrosome counts, and cGAS–STING activation profiling—help annotate the functional consequences of CIN.

For longitudinal monitoring, plasma or cerebrospinal fluid-derived cell-free DNA analyzed through whole-genome sequencing and targeted CNV panels can track dominant clones and emergent aneuploid subclones throughout treatment. Liquid biopsies combined with computational deconvolution could detect resistant karyotypes before radiographic progression, offering a window for timely therapeutic adaptation. Integrating a standardized CIN score, derived from CNV burden, structural complexity, and micronucleus index, into clinical pathology reports would allow stratification of patients into biomarker-driven therapeutic arms. The following table illustrates potential stratification:

Patient Stratification Based on CIN Status

Defining and applying CIN patterns in glioblastoma holds great promise for the development of personalized medicine. Distinct CIN architectures correspond to unique vulnerabilities. The table below details these associations:

CIN Architectures and Corresponding Therapeutic Vulnerabilities

Dynamic monitoring of clonal CNV shifts could guide adaptive therapy design, enabling early intervention before the establishment of resistant populations. Furthermore, understanding the interplay between micronucleus burden, cGAS–STING activation, and the immune microenvironment could inform rational combinations of immunotherapies with agents that transiently augment cytosolic DNA to boost antitumor immunity without inducing immune exhaustion.

In conclusion, CIN represents both a challenge and an opportunity in glioblastoma management. Transitioning from descriptive observation to actionable biomarker status requires the standardization of CIN features, the adoption of scalable single-cell and cytogenetic platforms to trace clonal evolution, and the integration of CIN metrics into trial designs and pathology workflows. Only by conceptualizing CIN as a quantifiable and manipulable biomarker—rather than as a manifestation of genomic disarray—can clinicians anticipate resistance, design adaptive regimens, and harness tumor evolution for therapeutic gain. The field must now prioritize longitudinal, lineage-resolved studies that couple single-cell lineage tracing, biochemical and cytogenetic assays, and liquid biopsy monitoring with interventional trials testing CIN-guided strategies. Such integrated efforts will determine whether deciphering CIN patterns can transform glioblastoma's intrinsic genomic instability from a source of therapeutic frustration into a foundation for personalized and evolution-informed medicine.

The authors declare no conflicts of interest.